Cantor Fitzgerald Reiterates Neutral on Rigel Pharmaceuticals, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska has reiterated a Neutral rating for Rigel Pharmaceuticals (NASDAQ:RIGL) and maintained a price target of $15.
September 20, 2024 | 4:30 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cantor Fitzgerald has reiterated a Neutral rating for Rigel Pharmaceuticals, maintaining a $15 price target. This suggests that the analyst sees no immediate catalysts for significant price movement.
The reiteration of a Neutral rating and maintenance of the price target at $15 indicates that the analyst does not foresee significant changes in the stock's performance in the short term. This suggests stability rather than volatility, which is why the score is neutral.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100